#ATEMPT also looked at "right sizing" treatment w/ T-DM1 for small #HER2 #bcsm w/ similar fantastic outcomes.
ATEMPT2.0 will examine 6 months of T-DM1 as 1 yr was actually a bit harder to tolerate than we expected
#SABCS22 @OncoAlert@twitter.com
@PTarantinoMD@twitter.com @stolaney1@twitter.com